Earn points on every order · Free shipping on orders over $159 · New products in stock
← Back to Compound Library
Growth Hormone Axis

GHRP-6

The original ghrelin-mimetic GH-releaser. Same GH-boosting mechanism as GHRP-2 but with a much stronger appetite kick, favored when the goal is eating more and gaining.

Research referenceCommunity compiled
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

The original ghrelin-mimetic GH-releaser.

Same GH-boosting mechanism as GHRP-2 but with a much stronger appetite kick, favored when the goal is eating more and gaining.

What It Does

GHRP-6 is a GHS-R1a (ghrelin receptor) agonist that triggers a GH pulse and powerfully stimulates hunger.

Mild cortisol and prolactin rise.

Combined with a GHRH analog (Sermorelin/CJC) the GH release is far larger than either alone.

The strong appetite makes it a bulking-phase tool and a less ideal choice when cutting.

Reconstitution

Vial SizeBAC Water / SolventConcentration
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Protocol

PhaseFrequencyAmountNotes
Weeks 1–22×/day100 mcgExpect strong hunger ~20–30 min after dosing. AM fasted + pre-bed.
Weeks 3–122–3×/day200 mcgWorking dose. ~1 mcg/kg saturates the GH response; more mainly adds cortisol/prolactin.
Off4 weeks–Prevents ghrelin-receptor downregulation.
Cycle & Timing

8–12 weeks on / 4 weeks off.

Timing

Empty stomach, no food 30 min after. The hunger surge is the tell that it’s working (and why it suits bulking). Saturation: plateaus ~1 mcg/kg.

Population Considerations

Women need more GH but get a bigger bump from ghrelin-types, though these raise prolactin, which can disrupt cycles/ovulation (watch for missed periods). Oral estrogen blunts IGF-1. Men: Men overshoot the IGF-1 ceiling more easily (aim mid-normal); high prolactin lowers libido and testosterone, switch to a cleaner option if it cli Women need more GH but get a bigger bump from ghrelin-types, though these raise prolactin, which can disrupt cycles/ovulation (watch for missed periods). Oral estrogen blunts IGF-1. Men: Men overshoot the IGF-1 ceiling more easily (aim mid-normal); high prolactin lowers libido and testosterone, switch to a cleaner option if it climbs.

Handling & Stacking

Injection site
SubQ, abdomen. Rotate.
Storage
Freeze-dried: -4°F. Reconstituted: 36–46°F. Best used within 28 days, otherwise potency gradually fades over ~3–4 weeks (structure-based estimate, no published data).
Side effects
Pronounced hunger, flushing/warmth, water retention, mild cortisol/prolactin bump. Hunger fades with continued use.
What to expect
  • Strong appetite and improved sleep early; recovery and body-composition gains over 8–12 weeks.
  • Best in a GHRH + GHRP stack during a gaining phase.
  • Supply math 5mg → 7 vials | 10mg → 4 vials (12-wk @ 200 mcg × 2/day)
Pairs well with
CJC-1295 (No DAC) / Sermorelin (GHRH + GHRP synergy); Ipamorelin (if appetite is unwanted); Wolverine Blend (recovery)
Avoid
Active malignancy. Severe insulin resistance. Cutting phases (appetite). Elevated baseline prolactin
Approved drug
Somatropin (HGH) is approved for growth-hormone deficiency and tesamorelin (Egrifta) for HIV lipodystrophy. Secretagogues like this one are off-label.

Safety & Patient Education

Contraindications
Active malignancy of any kind (GH/IGF-1 can promote tumor growth) Severe diabetic retinopathy Acute critical illness (per somatropin label) Pregnancy and lactation
Warnings
Strong appetite stimulation, can drive unwanted weight gain, poor glycemic control and insulin resistance with sustained use Cortisol and prolactin elevation (similar to GHRP-2) Fluid retention, carpal tunnel, joint pain with extended use IGF-1 elevation: theoretical malignancy promotion beyond physiological ranges Requires off cycles to prevent receptor desensitization
Drug interactions
Glucocorticoids: blunt GH response Insulin / antidiabetics: GH + appetite worsen glycemic control, monitor closely Levothyroxine: GH lowers free T4, recheck TSH/fT4 quarterly Oral estrogens: blunt GH-stimulated IGF-1
Labs
  • IGF-1 (baseline + Week 8 + end) Fasting glucose / HbA1c (baseline + end), especially given appetite effect Prolactin if symptomatic Age-appropriate cancer screening before starting Out of range?
  • IGF-1 above your age range = too much growth signal (feeds hidden cancer, enlarges organs) → drop the dose; rising glucose/HbA1c = sugar creeping up.
Stop criteria
Fasting glucose rises >20 mg/dL above baseline IGF-1 above upper limit of normal for age Uncontrolled appetite-driven weight gain New persistent joint pain, carpal tunnel, or vision changes
Patient education
Expect strong hunger, plan meals or it can sabotage a cut Keep doses near the saturating range; more isn’t better Fasted dosing; protect sleep Not for use during active malignancy or pregnancy; report new lumps or vision changes
References
researchdosing · peptidedosages · PubMed · thepeptidereport · Span 2000 · Weissberger 1991